{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:24:21Z","timestamp":1781670261065,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.clinthera.2007.04.005","type":"journal-article","created":{"date-parts":[[2007,7,6]],"date-time":"2007-07-06T11:20:34Z","timestamp":1183720834000},"page":"535-562","source":"Crossref","is-referenced-by-count":63,"title":["Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus"],"prefix":"10.1016","volume":"29","author":[{"given":"Devada","family":"Singh-Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gazze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.04.005_bib1","series-title":"Total prevalence of diabetes & pre-diabetes","author":"American Diabetes Association","year":"2006"},{"key":"10.1016\/j.clinthera.2007.04.005_bib2","series-title":"Complications of diabetes in the United States","author":"American Diabetes Association","year":"2006"},{"key":"10.1016\/j.clinthera.2007.04.005_bib3","series-title":"Direct and indirect costs of diabetes in the United States","author":"American Diabetes Association","year":"2006"},{"key":"10.1016\/j.clinthera.2007.04.005_bib4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care."},{"key":"10.1016\/j.clinthera.2007.04.005_bib5","series-title":"FDA approves new drug to treat type 1 and type 2 diabetes","author":"FDA Talk Paper","year":"2005"},{"key":"10.1016\/j.clinthera.2007.04.005_bib6","series-title":"Pharmacotherapy, a Pathophysiologic Approach","first-page":"1333","article-title":"Diabetes mellitus","author":"Triplitt","year":"2005"},{"key":"10.1016\/j.clinthera.2007.04.005_bib7","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1172\/JCI111542","article-title":"Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus","volume":"74","author":"Ward","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2007.04.005_bib8","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1210\/jc.2004-0405","article-title":"Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes","volume":"89","author":"Hull","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2007.04.005_bib9","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1210\/jc.85.11.4053","article-title":"Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus","volume":"85","author":"Shah","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2007.04.005_bib10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/diacare.23.5.650","article-title":"Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance","volume":"23","author":"Larsson","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.04.005_bib11","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s001250100003","article-title":"Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations","volume":"44","author":"Ahren","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.04.005_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1046\/j.1365-2362.2003.01142.x","article-title":"Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects","volume":"33","author":"Ludvik","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clinthera.2007.04.005_bib13","first-page":"8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987"},{"key":"10.1016\/j.clinthera.2007.04.005_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF00404025","article-title":"Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans","volume":"34","author":"Hartter","year":"1991","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.04.005_bib15","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0196-9781(01)00515-0","article-title":"Adrenomedullin and related peptides: Receptors and accessory proteins","volume":"22","author":"Muff","year":"2001","journal-title":"Peptides"},{"key":"10.1016\/j.clinthera.2007.04.005_bib16","doi-asserted-by":"crossref","first-page":"E484","DOI":"10.1152\/ajpendo.2000.278.3.E484","article-title":"High-frequency oscillations in circulating amylin concentrations in healthy humans","volume":"278","author":"Juhl","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2007.04.005_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0140-6736(92)90785-2","article-title":"Amylin concentrations and glucose control","volume":"339","author":"Koda","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2007.04.005_bib18","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.40.12.1615","article-title":"Decrease of stimulated amylin release precedes impairment of insulin secretion in type 2 diabetes","volume":"40","author":"Ludvik","year":"1991","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2007.04.005_bib19","first-page":"E903","article-title":"Distribution and kinetics of amylin in humans","volume":"274","author":"Clodi","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clinthera.2007.04.005_bib20","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1172\/JCI117558","article-title":"Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion","volume":"94","author":"Ludvik","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2007.04.005_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1006\/bbrc.1997.7465","article-title":"Renal elimination of islet amyloid polypeptide","volume":"239","author":"Leckstrom","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2007.04.005_bib22","doi-asserted-by":"crossref","first-page":"36621","DOI":"10.1074\/jbc.M006170200","article-title":"Degradation of amylin by insulindegrading enzyme","volume":"275","author":"Bennett","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2007.04.005_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/eje.0.1330017","article-title":"Calcitonin, calcitonin gene-related peptide, adrenomedullin, and amylin: Homologous peptides, separate receptors and overlapping biological actions","volume":"133","author":"Muff","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinthera.2007.04.005_bib24","first-page":"493","article-title":"High affinity amylin binding sites in rat brain","volume":"44","author":"Beaumont","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2007.04.005_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/pr.54.2.233","article-title":"International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors","volume":"54","author":"Poyner","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2007.04.005_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/mol.56.1.235","article-title":"Multiple amylin receptors arise from receptor activitymodifiying pro tein interaction with the calcitonin receptor gene product","volume":"56","author":"Christopoulos","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2007.04.005_bib27","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1210\/en.140.6.2924","article-title":"An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3","volume":"140","author":"Muff","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2007.04.005_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","article-title":"Dose-response for glucagonostatic effect of amylin in rats","volume":"46","author":"Gedulin","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2007.04.005_bib29","first-page":"A154","article-title":"Amylin inhibition of arginineinduced glucagon secretion: Com parison with glucagon-like peptide-1 (7-36)-amine (GLP-1)","volume":"39","author":"Gedulin","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.04.005_bib30","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/BF00401833","article-title":"Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin","volume":"38","author":"Young","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.04.005_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-0495(96)90192-4","article-title":"Doseresponses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7\u201336) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake","volume":"45","author":"Young","year":"1996","journal-title":"Metabolism"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2007.04.005_bib32","first-page":"187A","article-title":"Insulin-induced hypoglycemia reverses amylin inhibition of gastric emptying in rats","volume":"45","author":"Young","year":"1996","journal-title":"Diabetes."},{"key":"10.1016\/j.clinthera.2007.04.005_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2337\/diaclin.20.3.137","article-title":"Amylin replacement with Pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy","volume":"20","author":"Buse","year":"2002","journal-title":"Clin Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2007.04.005_bib34","first-page":"235A","article-title":"Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve","volume":"45","author":"Jodka","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2007.04.005_bib35","unstructured":"Symlin[package insert]. San Diego, Calif. Amylin Pharmaceuticals, Inc; 2005."},{"key":"10.1016\/j.clinthera.2007.04.005_bib36","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2337\/diabetes.54.4.1100","article-title":"The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes","volume":"54","author":"Heptulla","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2007.04.005_bib37","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ajhp\/62.8.816","article-title":"Properties of Pramlintide and insulin upon mixing","volume":"62","author":"Weyer","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2007.04.005_bib38","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: A dose-timing study","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.04.005_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: A dose-timing study","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2007.04.005_bib40","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/meta.2002.32022","article-title":"The human amylin analog, Pramlintide, corrects postprandial hyper glucagonemia in patients with type 1 diabetes","volume":"51","author":"Fineman","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2007.04.005_bib41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human amylin analog, pram-lintide, reduces postprandial hyper glucagonemia in patients with type 2 diabetes mellitus","volume":"34","author":"Fineman","year":"2002","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.clinthera.2007.04.005_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s001250050949","article-title":"The effect of single doses of pram-lintide on gastric emptying of two meals in men with IDDM","volume":"41","author":"Kong","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.04.005_bib43","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.2000.278.6.G946","article-title":"Pramlintide, an amylin analog, selectively delays gastric emptying: Potential role of vagal inhibition","volume":"278","author":"Samsom","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.clinthera.2007.04.005_bib44","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","article-title":"Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes","volume":"48","author":"Chapman","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.04.005_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1389450053174596","article-title":"Pancreatic amylin as a centrally acting satiating hormone","volume":"6","author":"Lutz","year":"2005","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.clinthera.2007.04.005_bib46","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/diacare.28.3.632","article-title":"Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes","volume":"28","author":"Ceriello","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.04.005_bib47","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.04.005_bib48","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2007.04.005_bib49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2005-837662","article-title":"Adjunctive therapywith pramlintide lowers HbAlc without concomi tant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets","volume":"113","author":"Ratner","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.clinthera.2007.04.005_bib50","first-page":"A232","article-title":"Pramlintide therapy in addition to insulin in type 1 diabetes: Effect on metabolic control after 6 months","volume":"42","author":"Fineman","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.04.005_bib51","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.04.005_bib52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/dc06-1026","article-title":"Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes","volume":"30","author":"Marrero","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.04.005_bib53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.04.005_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulintreated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.clinthera.2007.04.005_bib55","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.metabol.2003.06.003","article-title":"Effect of pramlintide on Al C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: A pooled post hoc analysis","volume":"52","author":"Maggs","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2007.04.005_bib56","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin treated type 2 diabetes patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes Res"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.04.005_bib57","first-page":"A232","article-title":"Pramlintide therapy in addition to insulin in type 2 diabetes: Effect on metabolic control after 6 months","volume":"42","author":"Gottlieb","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.04.005_bib58","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","article-title":"Addition of pramlintide to insulin therapy lowers HbAlc in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets","volume":"5","author":"Hollander","year":"2003","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2007.04.005_bib59","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1463-1326.2004.00417.x","article-title":"The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes","volume":"7","author":"Amiel","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2007.04.005_bib60","doi-asserted-by":"crossref","DOI":"10.1007\/BF02830522","article-title":"Kinetics of pramlintide degradation in aqueous solution as a function of temperature and pH","volume":"1","author":"Kenley","year":"2000","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.clinthera.2007.04.005_bib61","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1191\/0960327103ht402oa","article-title":"Ex vivo human placental transfer of the peptides pramlintide and exena tide (synthetic exendin-4)","volume":"22","author":"Hiles","year":"2003","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.clinthera.2007.04.005_bib62","series-title":"Symlin (pramlintide acetate)","first-page":"666","year":"2006"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T04:49:00Z","timestamp":1556599740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807001051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0149291807001051"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.04.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}